The aim of this study is to compare between anti-10a levels in postpartum women receiving different prophylactic doses of LMWH: one group with LMWH doses adjusted by the women's weight and the second group receiving 1mg/kg to a maximum dose of 120 mg
pregnancy and postpartum period are associated with increased risk of thromboembolism. this risk is further increased in women with thrombophilia. This risk is higher in the postpartum period compared with pregnancy period, especially the risk for pulmonary embolism (PE). The American College Of Obstetrics and Gynecologists, The American college of chest physicians and The Royal College of obstetricians and gynecologists recommend using low molecular weight heparin during the postpartum period in women with thrombophilia and women with risk factor for developing thromboembolism. there is no specific guidelines regarding the best protocol based on the level of anti-10 a. This study will compare between two protocols based on anti-10a levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
136
to compare tow doses of clexane for preventing VTE in postpartum women
Emek medical center
Afula, Israel
clexane dosing method in order to achieve anti 10a level >0.2
Time frame: 4 hour after the women receive the drug
incidence of anti 10a level of >0.6
Time frame: 4 hour after the women receive the drug
incidence of vein thromboembolism
Time frame: during the six weeks after delivery
incidence of bleeding events
Time frame: during the six weeks after delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.